Prostaglandin D2 inhibits TGF-β1-induced epithelial-to-mesenchymal transition in MDCK cells

American Journal of Physiology - Renal Physiology

Volumn 291, Issue 6, 2006, Pages

  Zhang, Aihua ^a   Dong, Zheng ^b,c   Yang, Tianxin ^a  

^a UNIVERSITY OF UTAH   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Madin Darby canine kidney cells; Reactive oxygen species; Transforming growth factor 1

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 3 BENZYL 5 (6 CARBOXYHEXYL) 1 (2 CYCLOHEXYL 2 HYDROXYETHYLAMINO)HYDANTOIN; 5 (6 CARBOXYHEXYL) 1 (3 CYCLOHEXYL 3 HYDROXYPROPYL)HYDANTOIN; 8 BROMO CYCLIC AMP; ALPHA SMOOTH MUSCLE ACTIN; BERAPROST; CARBOCYCLIC THROMBOXANE A2; FORSKOLIN; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN F2 ALPHA; RAMATROBAN; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; 15 DEOXYPROSTAGLANDIN J2; 15-DEOXYPROSTAGLANDIN J2; ACTIN; CADHERIN; CYCLIC AMP; DRUG DERIVATIVE; PROSTAGLANDIN RECEPTOR; THROMBOXANE A2;

ANIMAL CELL; ARTICLE; DOG; DRUG EFFECT; EPITHELIUM CELL; MESENCHYME CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CELL LINE; DRUG INTERACTION; FIBROSIS; KIDNEY TUBULE; MESODERM; METABOLISM; PATHOLOGY;

ACTINS; ANIMALS; CADHERINS; CELL LINE; CYCLIC AMP; DINOPROST; DOGS; DRUG INTERACTIONS; EPITHELIAL CELLS; EPOPROSTENOL; FIBROSIS; KIDNEY TUBULES; MESODERM; PROSTAGLANDIN D2; REACTIVE OXYGEN SPECIES; RECEPTORS, PROSTAGLANDIN; THROMBOXANE A2; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33845365825     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00131.2006     Document Type: Article

References (52)

1. Arai I, Takano N, Hashimoto Y, Futaki N, Sugimoto M, Takahashi N, Inoue T, and Nakaike S. Prostanoid DP1 receptor agonist inhibits the pruritic activity in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 505: 229-235, 2004.
2. Bennett WM, Henrich WL, and Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 28: S56-S62, 1996.
3. Bonvalet JP, Pradelles P, and Farman N. Segmental synthesis and actions of prostaglandins along the nephron. Am J Physiol Renal Fluid Electrolyte Physiol 253: F377-F387, 1987.
4. Breyer MD and Breyer RM. G protein-coupled prostanoid receptors and the kidney. Annu Rev Physiol 63: 579-605, 2001.
5. Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, and Harris RC. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 62: 929-939, 2002.
6. Coleman RA, Smith WL, and Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46: 205-229, 1994.
7. Collino M, Patel NS, Lawrence KM, Collin M, Latchman DS, Yaqoob MM, and Thiemermann C. The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney Int 68: 529-536, 2005.
8. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM, Gorry SA, and Trzaskos JM. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378: 406-409, 1995.
9. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol 15: 290-301, 2000.
10. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 7: 2495-2508, 1996.
11. Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, and Fitzgerald GA. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306: 1954-1957, 2004.
12. Eguchi G and Kodama R. Transdifferentiation. Curr Opin Cell Biol 5: 1023-1028, 1993.
13. Faveeuw C, Gosset P, Bureau F, Angeli V, Hirai H, Maruyama T, Narumiya S, Capron M, and Trottein F. Prostaglandin D2 inhibits the production of interleukin-12 in murine dendritic cells through multiple signaling pathways. Eur J Immunol 33: 889-898, 2003.
14. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, and Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83: 803-812, 1995.
15. Guan Y and Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 60: 14-30, 2001.
16. Hammad H, de Heer HJ, Soullie T, Hoogsteden HC, Trottein F, and Lambrecht BN. Prostaglandin D2 inhibits airway dendritic cell migration and function in steady state conditions by selective activation of the D prostanoid receptor 1. J Immunol 171: 3936-3940, 2003.
17. Hermann M, Shaw S, Kiss E, Camici G, Buhler N, Chenevard R, Luscher TF, Grone HJ, and Ruschitzka F. Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. Hypertension 45: 193-197, 2005.
18. Hoffmann A, Nimtz M, and Conradt HS. Molecular characterization of beta-trace protein in human serum and urine: a potential diagnostic marker for renal diseases. Glycobiology 7: 499-506, 1997.
19. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, and Neilson EG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 110: 341-350, 2002.
20. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, and Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83: 813-819, 1995.
21. Lin SL, Chen RH, Chen YM, Chiang WC, Lai CF, Wu KD, and Tsai TJ. Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol 16: 2702-2713, 2005.
22. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15: 1-12, 2004.
23. Liu Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol 287: F7-F16, 2004.
24. Liu Y, Rajur K, Tolbert E, and Dworkin LD. Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways. Kidney Int 58: 2028-2043, 2000.
25. Melegos DN, Grass L, Pierratos A, and Diamandis EP. Highly elevated levels of prostaglandin D synthase in the serum of patients with renal failure. Urology 53: 32-37, 1999.
26. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, and Smithies O. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83: 473-482, 1995.
27. Nagata K, Tanaka K, Ogawa K, Kemmotsu K, Imai T, Yoshie O, Abe H, Tada K, Nakamura M, Sugamura K, and Takano S. Selective expression of a novel surface molecule by human Th2 cells in vivo. J Immunol 162: 1278-1286, 1999.
28. Narumiya S, Sugimoto Y, and Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 79: 1193-1226, 1999.
29. Nasrallah R and Hebert RL. Prostacyclin signaling in the kidney: implications for health and disease. Am J Physiol Renal Physiol 289: F235-F246, 2005.
30. Nasrallah R and Hebert RL. Reduced IP receptors in STZ-induced diabetic rat kidneys and high-glucose-treated mesangial cells. Am J Physiol Renal Physiol 287: F673-F681, 2004.
31. Nasrallah R, Landry A, Scholey JW, and Hebert RL. Characterization of the PGI2/IP system in cultured rat mesangial cells. Prostaglandins Leukot Essent Fatty Acids 70: 455-464, 2004.
32. Priem F, Althaus H, Birnbaum M, Sinha P, Conradt HS, and Jung K. Beta-trace protein in serum: a new marker of glomerular filtration rate in the creatinine-blind range. Clin Chem 45: 567-568, 1999.
33. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA, Werb Z, and Bissell MJ. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436: 123-127, 2005.
34. Ragolia L, Palaia T, Hall CE, Maesaka JK, Eguchi N, and Urade Y. Accelerated glucose intolerance, nephropathy, and atherosclerosis in prostaglandin D2 synthase knock-out mice. J Biol Chem 280: 29946-29955, 2005.
35. Rao PS, Cavanagh D, Dietz JR, Marsden KA, O'Brien WF, and Spaziani E. Dose-dependent effects of prostaglandin D2 on hemodynamics, renal function, and blood gas analyses. Am J Obstet Gynecol 156: 843-851, 1987.
36. Reilly CM, Oates JC, Sudian J, Crosby MB, Halushka PV, and Gilkeson GS. Prostaglandin J(2) inhibition of mesangial cell iNOS expression. Clin Immunol Immunopathol 98: 337-345, 2001.
37. Remuzzi G and Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456, 1998.
38. Rhyu DY, Yang Y, Ha H, Lee GT, Song JS, Uh ST, and Lee HB. Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J Am Soc Nephrol 16: 667-675, 2005.
39. Sanchez PL, Salgado LM, Ferreri NR, and Escalante B. Effect of cyclooxygenase-2 inhibition on renal function after renal ablation. Hypertension 34: 848-853, 1999.
40. Slattery C, Campbell E, McMorrow T, and Ryan MP. Cyclosporine A-induced renal fibrosis: a role for epithelial-mesenchymal transition. Am J Pathol 167: 395-407, 2005.
41. Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol Renal Fluid Electrolyte Physiol 263: F181-F191, 1992.
42. Smith WL, Garavito RM, and DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271: 33157-33160, 1996.
43. Spik I, Brenuchon C, Angeli V, Staumont D, Fleury S, Capron M, Trottein F, and Dombrowicz D. Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in mouse. J Immunol 174: 3703-3708, 2005.
44. Stahl PJ and Felsen D. Transforming growth factor-beta, basement membrane, and epithelial-mesenchymal transdifferentiation: implications for fibrosis in kidney disease. Am J Pathol 159: 1187-1192, 2001.
45. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
46. Tobian L, Uehara Y, and Iwai J. Prostaglandin alterations in barely hypertensive Dahl S rats. Trans Assoc Am Physicians 98: 378-383, 1985.
47. Uehara Y. PGD(2)/L-PGDS system in hypertension and renal injury. Nippon Yakurigaku Zasshi 123: 23-33, 2004.
48. Uehara Y. Prostaglandin D2. Nippon Rinsho 63, Suppl 8: 17-20, 2005.
49. Yang J and Liu Y. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 13: 96-107, 2002.
50. Yokoyama C, Yabuki T, Shimonishi M, Wada M, Hatae T, Ohkawara S, Takeda J, Kinoshita T, Okabe M, and Tanabe T. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation 106: 2397-2403, 2002.
51. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, and Kalluri R. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9: 964-968, 2003.
52. 2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor. Am J Physiol Renal Physiol 291: 1323-1331, 2006.